Biotech Industry · global
Ori Biotech Signs 10-Year Deal Worth Up to $120 Million to Automate Manufacturing of a Marketed Cell Therapy
Moving a cell therapy already used to treat patients onto a new manufacturing platform tests more than capacity. Ori’s new partnership will first establish comparability between the existing and new processes, taking a key step toward transforming commercial supply.
For therapies made from patients’ own cells, changes to manufacturing processes affect whether every batch can maintain consistent quality. Ori Biotech announced on September 15 that it had signed a 10-year partnership with an unnamed biopharmaceutical company to introduce its IRO automation platform into the manufacturing process for a marketed cell therapy. The immediate priority is to establish comparability between the existing and new processes.
According to Contract Pharma, the partnership covers services, milestones, equipment, and consumables purchases. Ori’s announcement and Pharma Manufacturing further stated that the total value over 10 years could reach up to $120 million. This figure is the combined ceiling for multiple categories of spending under the partnership; it should not be treated as money already paid, nor does it mean Ori has secured an equivalent amount of revenue.
What distinguishes this partnership from early-stage development platform testing is that the product is already being used in patients. Ori CEO Jason Foster confirmed to Pharma Manufacturing that the therapy has been approved for marketing and that the partner is evaluating whether to shift its existing core manufacturing capabilities to IRO. He also said the partner is one of seven developers in the United States with an approved autologous cell therapy. Neither the company nor the product has been named, so the indication and scale of supply involved cannot be confirmed.
IRO integrates hardware, consumables, software, and data analytics in a closed system. According to Ori, the platform aims to reduce manual operations and batch-to-batch variability, increase output, and lower manufacturing costs by automating and digitizing key steps. However, these are platform design goals. This announcement did not provide comparative data on costs, success rates, or quality following a manufacturing process change for the marketed product.
The real hurdle is whether the product can retain its required characteristics after the manufacturing method changes. The partnership currently aims to establish process comparability; the transfer of commercial production has not been completed. For patients, whether automation can shorten waiting times or increase supply still depends on subsequent validation, the regulatory procedures required for manufacturing process changes, and actual deployment results. The 10-year agreement itself cannot yet answer these questions.
Background
From Cellares’ automated manufacturing initiatives to expansions by cell therapy contract manufacturers, the industry is trying to move personalized treatments beyond the constraints of production that relies heavily on manual work. Ori’s approach in this partnership is to modify an existing process for a marketed product. It must meet demands for both greater efficiency and continued quality, making the task more challenging than simply adding equipment.
This long-term partnership shows that at least one commercial-stage developer is willing to commit resources to evaluating a transition to automated manufacturing. More substantive evidence will come from comparability validation results, the transition timeline, and whether supply can be increased steadily while maintaining quality. Only as these outcomes materialize might investment in the manufacturing platform translate into patients’ actual access to treatment.